Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor or Haplotype-Matched Donor in the Treatment of Patients at High-Risk or With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases or Malignancies

Basic Trial Information

Trial Description

Purpose:

Some types of lymphoma or lymphoproliferative disease are associated with Epstein-Barr virus. White blood cells from donors who are immune to Epstein-Barr virus may be an effective treatment for those cancers.

This phase I/II trial is studying the side effects and best dose of biological therapy in treating patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Eligibility:

Eligibility criteria include the following:

• Have a weakened immune system
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive infusions of white blood cells from donors who are immune to Epstein-Barr virus once a week for 3 weeks. Treatment may be repeated after a 3-week rest. After finishing treatment, patients will be evaluated periodically for 1 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Richard O'Reilly, MD, Protocol chair		Ph: 212-639-5957; 800-525-2225 Email: oreillyr@mskcc.org

U.S.A.
New York
	New York
	Memorial Sloan-Kettering Cancer Center
		Richard O'Reilly, MD	Ph:  212-639-5957 800-525-2225
			Email: oreillyr@mskcc.org

Registry Information
Official Title		An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients with Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases
Trial Start Date		1995-03-28
Trial Completion Date		2010-03-30 (estimated)
Registered in ClinicalTrials.gov		NCT00002663
Date Submitted to PDQ		1995-03-28
Information Last Verified		2010-05-07
NCI Grant/Contract Number		CA08748

Back to Top